Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/244—Lanthanides; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
  • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

• Hyperphosphataemia is a particular problem of patients with chronic renal insufficiency using dialysis equipment and with about 70% of patients with end stage renal disease (ESRD). This condition can lead to severe bone problems and metastatic calcification of major organs and is associated with significant morbidity and mortality.
• Conventional dialysis fails to reduce the levels of phosphate in the blood, so that levels rise in time. Elevated phosphate levels are treated using a combination of dietary restrictions and phosphate-binding agents.
• Another problem of patients with chronic renal insufficiency is secondary hyperparathyroidism. It is also important in patients with chronic renal insufficiency to avoid and treat secondary hyperparathyroidism.
• This invention relates to a chewable lanthanum formulation
• a chewable lanthanum formulation comprising: a) a pharmaceutically effective amount of a lanthanum compound; and b) at least one chewable pharmaceutically acceptable excipient.
• This invention relates to a palatable lanthanum formulation
• a palatable lanthanum formulation comprising: a) a pharmaceutically effective amount of a lanthanum compound; and b) at least one pharmaceutically acceptable excipient, the formulation being palatable to a mammal, e.g., humans, cats, dogs, etc.
• This invention relates to a sprinklable lanthanum formulation comprising; a) a pharmaceutically effective amount of a lanthanum compound; and b) at least one pharmaceutically acceptable excipient.
• This invention relates to a method for controlling hyperphosphataemia in a patient comprising administering a therapeutically effective amount of a lanthanum compound in a palatable formulation.
• This invention relates to a method for controlling hyperphosphataemia in a patient comprising administering a therapeutically effective amount of a lanthanum compound in a chewable formulation.
• This invention relates to a method for controlling hyperphosphataemia in a patient comprising administering a therapeutically effective amount of a lanthanum compound in a sprinklable formulation.
• This invention relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture and; b) compressing the mixture into a tablet or filing up the resulting mixture in an appropriate container.
• This invention relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and c) compressing the mixture into a tablet or filing up the resulting mixture in a appropriate container.
• This invention relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of compressing the lanthanum compound into a slug material or roller compacting into a strand material, and milling the prepared material into a free flowing material, then blending with excipients, the resulting combination is compressed into a tablet or filing up the resulting mixture in a appropriate container.
• such formulation is also chewable and/or sprinklable and/or palatable and the lanthanum carbonate is in a desired hydration state.
• This invention relates to a pharmaceutical formulation in a chewable tablet comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; and b) compressing the mixture into a tablet.
• This invention relates to a process for preparing a formulation of a lanthanum compound which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture.
• This invention relates to a process for preparing a tablet formulation of a lanthanum compound which comprises the steps of: a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; and b) compressing the mixture into a tablet.
• the present invention is directed to a process for obtaining the formulation of the present invention.
• the hydration state of the lanthanum compound present in the formulation of the present invention is relevant to the biological properties of the product. It is therefore desirable to maintain a stable hydration status of the lanthanum compound.
• the starting lanthanum compound is lanthanum carbonate as defined herein, it is desired to maintain hydration levels constant throughout the formulation process. This represents an additional challenge to obtaining a tablet or powder that is acceptable to the patient. It is important to mention that certain lanthanum compounds, such as lanthanum carbonate have poor flow characteristics.
• the invention relates to such a method for treating hyperphosphataemia in a renal failure patient, including but not limited to a patient receiving dialysis and a patient with end-stage renal disease (ESRD), comprising administering a therapeutically effective amount of a lanthanum compound.
• a renal failure patient including but not limited to a patient receiving dialysis and a patient with end-stage renal disease (ESRD), comprising administering a therapeutically effective amount of a lanthanum compound.
• ESRD end-stage renal disease
• the invention relates to such a method for treating a chronic kidney disease patient comprising administering a therapeutically effective amount of a lanthanum compound.
• the invention relates to a method for controlling hyperparathyroidism in a patient with chronic renal insufficiency comprising administering a therapeutically effective amount of a lanthanum compound, preferably lanthanum carbonate.
• the invention relates to a method for treating hyperparathyroidism in a patient with chronic renal insufficiency comprising administering a therapeutically effective amount of a lanthanum compound, preferably lanthanum carbonate.
• the lanthanum compound is administered in such a formulation such that plasma levels of lanthanum are low, e.g., at least as good as those provided by a mean concentration curve where C max , T max and AUC are preferably less than 1.5 ng/ml, about 12 hours, and less than 50 ng.hr/ml, respectively, for a dose of 3g per day (e.g., Ig three times a day), such as is achieved in the prior art.
• C max and AUC are less than 1.1 ng/ml and less than 32 ng.hr/ml, and in a most preferred embodiment, C max and AUC are less than 0.5 ng/ml and less than 20 ng.hr/ml, of such dosage.
• T max values are essentially unaffected by dose and C ma x and AUC values vary linearly with dosage. All of these parameters have their highly conventional meanings.
• the invention in another embodiment, relates to a method of treating hyperphosphataemia comprising administering to a patient in need thereof such a lanthanum carbonate formulation.
• Preferred lanthanum compounds include lanthanum carbonate compounds.
• Lanthanum carbonate compounds refer to all forms of lanthanum carbonate.
• the invention relates to lanthanum carbonate of the general formula: La 2 (CO 3 ) 3 » xH 2 O where x has a value from 3 to 8, from 3 to 7, from 3 to 6, preferably from 3 to 5, more preferably from 3 to 4, more preferably from 3 to 4.5, preferably from 4 to 5, most preferably 3.4, most preferably x has an average value of 4; for the preparation of a medicament for the treatment of hyperphosphataemia by administration into the gastrointestinal tract; see e.g., U.S. Patent No. 5,968,976 which is incorporated herein by reference.
• the hydration level of the lanthanum compound can be measured by methods well known in the art, such as thermal analysis (TGA).
• the excipients used in the formulation of the present invention are suitable for administration to renally impaired patients.
• the excipients include diluents, binders, and lubricants/glidants. It is understood that other agents such as disintegrant, colors, flavors/sweeteners can be added to the formulation.
• the diluents can be chosen from dextrates, corn syrup, oligosaccharide, isomaltooligosaccharide, glucose, lycasin, xylitol, lactitol, erythritol, mannitol, isomaltose, polydextrose, dextrin, starch, fructose, xylitol, maltodextrin, maltitol, isomalt, lactose, sorbitol, microcrystalline cellulose (such as avicel), sucrose based diluent-binders (such as Nutab, Di-Pac or Sugartab), confectioner's sugar, calcium sulfate dihydrate, calcium lactate trihydrate, hydrolysed starches (such as Emdex or Celutab), dextrose (such as Cerelose), inositol, hydrolyzed cereal solids (such as Maltrons or Mor-Rex), amylose or glycine.
• the diluents can be chosen from dextrates, starch, lactose, mannitol, sorbitol, microcrystalline cellulose (such as avicel), sucrose based diluent-binders (such as Nutab, Di-Pac or Sugartab), confectioner's sugar, calcium sulfate dihydrate, calcium lactate trihydrate, hydrolysed starches (such as Emdex or Celutab), dextrose (such as Cerelose), inositol, hydrolyzed cereal solids (such as Maltrons or Mor-Rex), amylose or glycine.
• the diluents can be chosen from dextrates, starch, lactose, mannitol, sorbitol, microcrystalline cellulose (such as avicel), sucrose based diluent-binders (such as Nutab, Di-Pac or Sugartab), calcium sulfate dihydrate, calcium lactate trihydrate, hydrolysed starches (such as Emdex or Celutab), dextrose (such as Cerelose), inositol, or amylose.
• dextrates starch, lactose, mannitol, sorbitol, microcrystalline cellulose (such as avicel), sucrose based diluent-binders (such as Nutab, Di-Pac or Sugartab), calcium sulfate dihydrate, calcium lactate trihydrate, hydrolysed starches (such as Emdex or Celutab), dextrose (such as Cerelose), inositol, or amylose.
• the diluent is chosen from dextrates, fructose, xylitol, erythritol, maltodextrin, dextrose, maltitol, isomalt or glucose.
• the diluent is dextrates.
• lubricant/glidants and blending/flow agents can be chosen from for example magnesium stearate, talc, polyethylene glycol, silica, colloidal anhydrous silica, hydrogenated vegetable oils, glyceryl behenate or glyceryl monostearate.
• lubricant/glidants and blending/flow agents can be chosen from for example magnesium stearate, talc, polyethylene glycol, silica or colloidal anhydrous silica
• the invention is directed to a chewable formulation comprising:
• the invention is directed to a formulation comprising:
• the invention is directed to a chewable formulation comprising:
• the invention is directed to a formulation comprising:
• the invention is directed to a formulation comprising:
• the invention is directed to a formulation comprising:
• the invention is directed to a chewable formulation comprising:
• formulations are also sprinklable when manufactured in a conventional, applicable dosage form, e.g.beads, crushed tablets, powder, sieved granules, all are palatable.
• the formulation can either sprinkled onto a spoon or onto food if needed.
• Tablets may be coated according to methods well known in the art. It may be advantageous to incorporate an antioxidant, for example ascorbic acid, butylated hydroxyanisole or hydroquinone in the formulations of the invention to enhance their storage life.
• an antioxidant for example ascorbic acid, butylated hydroxyanisole or hydroquinone
• administration may be conducted in an uninterrupted regimen; such a regimen may be a long term regimen, e.g. a permanent regimen.
• the invention is directed to a pharmaceutical formulation in a tablet containing an amount of elemental lanthanum selected from 250 mg, 500mg, 750 mg and lOOOmg, produced by a process which comprises the steps of: a) dry admixing a lanthanum compound and excipient in a mixer to form a mixture; and b) compressing the mixture into tablets using a single punch or rotary tablet machine.
• a typical dosage for an adult may be, e.g., 750mg-3000mg daily.
• the dose can be divided and taken with each meal, for example 250-1000mg, e.g., three times per day.
• Serum plasma levels can be monitored weekly until an optimal serum phosphate level is reached conventionally.
• Lanthanum is a rare earth element with an atomic number of 57.
• the properties of lanthanum make this agent a good candidate as a useful phosphate binder. It has a high affinity for binding phosphorous and in the form of its carbonate salt, has a low solubility that limits gastrointestinal absorption.
• the phosphate binding is independent of pH, it possesses a low toxic potential based on the LD 5 o, it is palatable, abundant, and has limited effects on serum electrolyte concentrations (Hutchison, AJ et al. (1998) Pent. Dial. Int. 18(Suppl 2): S38.
• the dosages of formulations and the duration of administration according to the invention will vary depending on the requirements of the particular subject.
• the precise dosage regime will be determined by the attending physician or veterinary surgeon who will, inter alia, consider factors such as body weight, age and symptoms (if any).
• the formulations may if desired incorporate one or more further active ingredients.
• the present invention relates to a veterinary use of a lanthanum compound for the treatment of a non-human animal, e.g. a companion animal suffering from hyperphosphaetemia comprising the step of administering a pharmaceutically acceptable amount of a lanthanum compound to such an animal, e.g. a companion animal in need of such treatment.
• US patent No. 5,824,336 describes the need for a palatable anti-helminthic composition for companion animals and is specifically directed to a chewable tablet composition of flubendazole that is palatable to dogs.
• veterinary handbooks for cat owners typically caution against breaking up pills into powders.
• lanthanum compounds can be administered to animals, including companion animals in a palatable amount effective to mitigate hyperphosphataemia. Further, it has been discovered that the degree to which a lanthanum compound is palatable in such animals permits such compounds to be administered in a dosage form in which special coatings, masking components and administration procedures are not required to encourage consumption, especially when put into the animal's food ration. In particular, it has been discovered that lanthanum compounds can be administered to cats in an amount effective to mitigate hyperphosphataemia when in a particulate form for admixture with food. Accordingly, in one aspect the invention is directed to a method for treating hyperphosphaetemia in a companion animal comprising the step of administering a pharmaceutically acceptable amount of a lanthanum compound to a companion animal in need of such treatment.
• administration may be effected once or more times per day, for example once, twice, three or four times per day.
• Figure 1 shows the mean concentration of lanthanum in serum (lanthanum given at maximally tolerated dose for 72 hours).
• Figure 2 shows the mean concentration of inorganic phosphorus in urine.
• the manufacturing process involves sieving and blending the active ingredient with the excipients followed by direct compression. More specifically the steps are as follows for the 250mg and 500mg Formulation A tablets: a) Pass the lanthanum carbonate, dextrates and colloidal silicon dioxide through a screen of at least 16-mesh into a suitable blender and blend for about 20 minutes, b) Pass the talc (optional) and magnesium stearate through a 30-mesh screen and add to the blender and blend for about 5 minutes. c) Compress the blend using standard tooling to the target compression weight.
• Units are ng/gm. Conversion to ng/ml, multiply plasma concentrations by 1.054, density of plasma. The ranges and the upper range values of the mean plasma lanthanum levels are similar across the Phasell/III studies with the highest mean level at ⁇ 1 ng/ml. The range values were similarly low as the values of C max that were determined in earlier studies. 2. This study evaluates the primary and safety pharmacology of a conventional non-calcium anti-hyperphosphataemia treatment, lanthanum carbonate (LC).
• LC lanthanum carbonate
• LC is equipotent with AH and significantly more potent than CC or calcium acetate. LC is most effective (97.5% phosphate bound) at pH 3, but also has good efficacy at pH 5 and 7.
• LC is equipotent with AH and significantly more potent than CC or SH at reducing urinary phosphate excretion, a sensitive marker of dietary phosphate binding in this model.
• doses up to 2000 mg/kg LC has no direct effects on serum calcium, vitamin D or PTH levels and no adverse pharmacological actions on cardiovascular, respiratory or GI systems in mice, rats or dogs. No acute or long- term effects on CNS function occur in mice or dogs in Irwin and neurotoxicity screens.
• LC has no pro- or anti-convulsive activity and no effects on locomotor activity in mice.
• This 2-year multicenter, randomized, open-label, parallel-group trial consists of a 1- to 3-week washout period, a 6-week titration phase and a long- term maintenance phase.
• Hemodialysis patients with serum phosphorus > 5.9 mg/dL (> 1.9 mmol/L) receive either LC (375-3000 mg/day elemental lanthanum) or their pre-study phosphate binder.
• the primary aim of the study is to evaluate safety and tolerability over 2 years.
• the main efficacy endpoint is control of serum phosphorus ⁇ 5.9 mg/dL. Results In total, 647 patients receive LC and 642 receive standard therapy (calcium agents: 78%; sevelamer: 16%).
• Treatment-emergent adverse events occur with greater frequency in the standard therapy group than the LC group included hypercalcemia (10.4 vs. 3.4%), diarrhea (27.4 vs. 19.8%), abdominal pain (20.9 vs. 14.1%) and dyspepsia (14.8 vs. 8.2%o).
• Serious adverse events are also more frequent in the standard- treatment group (65.4 vs. 51.0%). However, this is likely to be complicated by the difference in treatment exposure between groups. Plasma lanthanum remains very low throughout treatment (mean level: 0.5-0.6 ng/mL).
• LC shows equivalent efficacy to CC in controlling serum phosphorus in patients with end-stage renal disease. LC is well tolerated, with a lower risk of hypercalcaemia than CC.
• Serum phosphorus levels are maintained at around 1.8 mmol/L (5.6 mg/dL) in both groups over 24 weeks: mean endpoint values were 1.76 mmol/L in the LC/LC group and 1.83 mmol/L in the CC/LC group.
• serum phosphorus is controlled in 63.3% of the LC/LC group, compared with 58.3% of the CC/LC group.
• the most common treatment-emergent adverse events are gastrointestinal, while those considered to be related to study treatment are reported by 17% of LC/LC patients and 31% of CC/LC patients. Hypercalcemic episodes are reported by 0.3% of patients in the LC/LC group and 2.7%> of patients in the CC/LC group.
• LC is well tolerated and effective for a period of at least 1 year.
• the reduced incidence of hypercalcemia observed with LC in short-term trials is maintained for 1 year.
• Safety analyses include adverse events, vital signs and plasma lanthanum.
• Efficacy assessments include serum phosphorus and parathyroid hormone (PTH). Results All 98 patients were included in the intent-to-treat efficacy and safety population.
• Adverse-event profiles were similar with LC and CC, but hypercalcemic events (serum calcium > 2.65 mmol/L) were much less frequent with LC (6%) than with CC (35%).
• Plasma lanthanum levels were similar in the LC- and CC-treated patients (range, 0.31-0.11 ng/mL) at baseline, and were higher in LC -treated patients ( ⁇ 0.03-1.95 ng/mL) than in CC-treated patients (all ⁇ 0.03 ng/mL) at endpoint. Plasma lanthanum reached steady state early in the study in LC-treated patients, and was similar between Weeks 8 and 52. LC and CC provided similar control of serum phosphorus.
• Baseline mean ( ⁇ SD) values were 1.72 ⁇ 0.39 and 1.87 ⁇ 0.52 mmol/L, and endpoint values were 1.79 ⁇ 0.47 and 1.65 ⁇ 0.54 mmol/L with LC and CC, respectively. Serum PTH remained stable with LC over 1 year, but decreased with CC.
• the study comprised 3 parts: a 1- to 3 -week screening and washout phase, a 4-week, open-label, dose-titration phase with LC, and a 4-week, double-blind, maintenance phase in which patients were randomized (1 :1) to receive LC or placebo.
• LC was administered as chewable tablets providing 250 or 500 mg lanthanum.
• Male and female haemodialysis patients were included who had serum phosphorus levels > 5.6 mg/dL (1.8 mmol/L) following washout of their previous phosphate binder.
• the study enrolled 103 patients.
• the primary efficacy endpoint was the serum phosphorus level obtained at the last week of double-blind treatment.
• the safety and tolerability profile of LC was assessed by monitoring of adverse events and vital signs at each study visit. Full biochemical and haematological screens were also undertaken, and plasma levels of lanthanum were measured throughout the study.
• Renal osteodystrophy is an important complication of hyperphosphataemia, associated with significant patient morbidity.
• Aluminum- based phosphate binders have been associated with bone toxicity and have thus added to the existing difficulties of ROD. This study was designed to demonstrate the lack of similar toxicity for conventional lanthanum carbonate (LC) and to compare its long-term effects on bone with those of calcium carbonate (CC).
• LC may therefore have an advantage over conventional phosphate binders when treating ROD.

Priority Applications (21)

Applications Claiming Priority (4)

Publications (1)

Family

ID=34221462

Family Applications (1)

Country Status (29)

Cited By (21)

Families Citing this family (23)

Citations (1)

Family Cites Families (50)

• 2004
  • 2004-08-26 SI SI200431437T patent/SI1660104T1/sl unknown
  • 2004-08-26 HU HUE09172030A patent/HUE024906T2/en unknown
  • 2004-08-26 JP JP2006524189A patent/JP4896719B2/ja active Active
  • 2004-08-26 PL PL10151270T patent/PL2172205T3/pl unknown
  • 2004-08-26 AT AT04761727T patent/ATE460169T1/de active
  • 2004-08-26 SI SI200432346A patent/SI2792363T1/sl unknown
  • 2004-08-26 PT PT91720300T patent/PT2133084E/pt unknown
  • 2004-08-26 NZ NZ545633A patent/NZ545633A/en unknown
  • 2004-08-26 SG SG200806201-0A patent/SG145765A1/en unknown
  • 2004-08-26 ES ES14167982.9T patent/ES2592803T3/es active Active
  • 2004-08-26 EP EP14167982.9A patent/EP2792363B1/en not_active Revoked
  • 2004-08-26 EP EP20090172030 patent/EP2133084B1/en active Active
  • 2004-08-26 DK DK14167982.9T patent/DK2792363T3/da active
  • 2004-08-26 SI SI200432228T patent/SI2133084T1/sl unknown
  • 2004-08-26 PT PT04761727T patent/PT1660104E/pt unknown
  • 2004-08-26 DK DK04761727.9T patent/DK1660104T3/da active
  • 2004-08-26 ES ES04761727T patent/ES2343354T3/es active Active
  • 2004-08-26 ES ES09172030.0T patent/ES2532389T3/es active Active
  • 2004-08-26 PT PT141679829T patent/PT2792363T/pt unknown
  • 2004-08-26 EA EA200970709A patent/EA200970709A1/ru unknown
  • 2004-08-26 KR KR1020067003792A patent/KR100830764B1/ko active IP Right Grant
  • 2004-08-26 MX MXPA06002257A patent/MXPA06002257A/es active IP Right Grant
  • 2004-08-26 PL PL04761727T patent/PL1660104T3/pl unknown
  • 2004-08-26 DK DK10151270T patent/DK2172205T3/da active
  • 2004-08-26 PL PL09172030T patent/PL2133084T3/pl unknown
  • 2004-08-26 HU HUE14167982A patent/HUE029382T2/en unknown
  • 2004-08-26 BR BRPI0413394A patent/BRPI0413394A8/pt not_active Application Discontinuation
  • 2004-08-26 CN CN2004800315788A patent/CN1871018B/zh active Active
  • 2004-08-26 EP EP04761727A patent/EP1660104B1/en active Active
  • 2004-08-26 CZ CZ200718525U patent/CZ17621U1/cs not_active IP Right Cessation
  • 2004-08-26 US US10/926,330 patent/US7465465B2/en active Active
  • 2004-08-26 EP EP20100151270 patent/EP2172205B1/en active Active
  • 2004-08-26 DE DE602004025950T patent/DE602004025950D1/de active Active
  • 2004-08-26 AU AU2004266050A patent/AU2004266050B2/en active Active
  • 2004-08-26 EA EA200600479A patent/EA012798B1/ru not_active IP Right Cessation
  • 2004-08-26 CA CA2536959A patent/CA2536959C/en active Active
  • 2004-08-26 PT PT10151270T patent/PT2172205E/pt unknown
  • 2004-08-26 WO PCT/CA2004/001563 patent/WO2005018651A1/en active Application Filing
  • 2004-08-26 DK DK09172030T patent/DK2133084T3/en active
  • 2004-08-26 SI SI200432171T patent/SI2172205T1/sl unknown
  • 2004-08-26 PL PL14167982T patent/PL2792363T3/pl unknown
  • 2004-08-26 DE DE202004021169U patent/DE202004021169U1/de not_active Expired - Lifetime
  • 2004-08-26 ES ES10151270.5T patent/ES2478258T3/es active Active
• 2006
  • 2006-02-15 IL IL173755A patent/IL173755A0/en not_active IP Right Cessation
  • 2006-03-15 IS IS8353A patent/IS2893B/is unknown
  • 2006-03-16 ZA ZA200602213A patent/ZA200602213B/xx unknown
  • 2006-03-24 NO NO20061347A patent/NO342559B1/no unknown
  • 2006-06-12 HK HK06106716.4A patent/HK1084338A1/xx unknown
  • 2006-09-22 FI FI20060387U patent/FI7568U1/fi not_active IP Right Cessation
  • 2006-09-26 DK DK200600252U patent/DK200600252U4/da not_active IP Right Cessation
  • 2006-10-19 AT AT0075706U patent/AT9809U1/de not_active IP Right Cessation
• 2008
  • 2008-09-24 US US12/237,381 patent/US20090017133A1/en not_active Abandoned
• 2009
  • 2009-06-18 AU AU2009202429A patent/AU2009202429B2/en active Active
• 2010
  • 2010-06-04 CY CY101100501T patent/CY1110241T1/el unknown
  • 2010-07-30 JP JP2010171525A patent/JP2010248247A/ja active Pending
• 2014
  • 2014-10-28 IL IL235371A patent/IL235371B/en active IP Right Grant
• 2016
  • 2016-09-22 CY CY20161100942T patent/CY1118211T1/el unknown

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events